olivLaw · US equity research
Artiva Biotherapeutics, Inc. ARTV
Biological Products, (No Diagnostic Substances) · SIC 2836 · Vertical: Biological Products, (No Diagnostic Substances) (SIC 2836)
Artiva Biotherapeutics develops off-the-shelf allogeneic NK cell therapies for B-cell driven autoimmune diseases, mainly refractory rheumatoid arthritis. In 2026 the company announced a Phase 3 design aligned with the FDA and a financing of about 300 million USD, which makes it relevant to the clinical stage of AlloNK.
The AI analysis may be outdated: new filings came after its sources (see the «AI analysis» section).
At the close of 05 Nov 2026, Artiva Biotherapeutics, Inc. (ARTV) stock was 4.13 USD (−2.13% on the day), with market capitalisation 201.9 m USD, beta 1.66, 52-week range 3.07–13.39 USD. Latest reported quarter (Q2 2026): net income of -25.0 m USD, diluted EPS -0.63 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 20.7
- oversold (≤ 30)
- Bollinger (20, 2)
- 3.36 – 7.53
- in the lower half of the band · %B 0.18 · band width 76.5%
- SMA 50 / 200
- 7.53 / 8.02
- downtrend (price < SMA50 < SMA200)
- MACD (12, 26, 9)
- -0.96 / -0.92
- MACD below signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −43.2% | −1.1% | −42.1 pp | — |
| 3 months | −64.3% | −0.5% | −63.9 pp | — |
| 6 months | −67.0% | +4.4% | −71.4 pp | — |
| Year to date | −3.7% | +12.3% | −16.0 pp | — |
| 1 year | +20.1% | +13.5% | +6.5 pp | −15.7% |
| 3 years | unavailable | +76.4% | unavailable | −7.9% |
| 5 years | unavailable | +63.7% | unavailable | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2026 · 30 Jun 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 ≈ | 0 | — | — | — | — | — | — |
| Research & development | 13.5 m | 13.3 m | 17.1 m | 17.9 m | 17.6 m | 17.0 m | 19.3 m | 21.9 m |
| Operating income | -18.3 m | -18.3 m | -22.2 m | -22.8 m | -22.9 m | -21.9 m | -24.4 m | -26.9 m |
| Depreciation & amortisation | 627.0 k ≈ | 614.0 k | 628.0 k | 641.0 k ≈ | 662.0 k ≈ | 666.0 k | 666.0 k | 692.0 k ≈ |
| Net income | -17.5 m | -16.1 m | -20.3 m | -21.3 m | -21.5 m | -20.8 m | -23.5 m | -25.0 m |
| Diluted EPS | -0.92 | -0.66 ≈ | -0.83 | -0.87 | -0.88 | -0.85 ≈ | -0.95 | -0.63 |
| Operating cash flow | -11.6 m ≈ | -14.7 m | -19.8 m | -23.0 m ≈ | -19.2 m ≈ | -14.7 m | -21.0 m | -20.4 m ≈ |
| Capex | 96.0 k ≈ | 64.0 k | 511.0 k | 1.1 m ≈ | 600.0 k ≈ | 421.0 k | 242.0 k | 415.0 k ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 33.5 m | 251.0 k | 0 |
| Revenue YoY | unavailable | −99.3% | −100.0% |
| Net income | -28.7 m | -65.4 m | -83.9 m |
| Net income YoY | unavailable | unavailable | unavailable |
| Diluted EPS | -35.78 | -5.81 | -3.43 |
| Diluted EPS YoY | unavailable | unavailable | unavailable |
| net % | -85.8% | -26,045.0% | unavailable |
| Free cash flow | -50.7 m | -55.7 m | -79.3 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 26.7 m USD
- Financial debt
- unavailable USD
- Net debt
- unavailable USD
- Equity
- 110.0 m USD
- Total assets
- 130.9 m USD
- Debt / equity
- unavailable
- Current ratio
- 8.61x
- ROE
- -56.5%
- ROA
- -49.3%
- FCF margin
- unavailable
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|
| Revenue | 33.5 m | 251.0 k | 0 | SEC (XBRL)· 10 Mar 2026verified |
| Research & development | 50.3 m | 50.3 m | 69.5 m | SEC (XBRL)· 10 Mar 2026verified |
| Operating income | -30.7 m | -67.3 m | -89.8 m | SEC (XBRL)· 10 Mar 2026verified |
| Depreciation & amortisation | 2.3 m | 2.4 m | 2.6 m | SEC (XBRL)· 10 Mar 2026verified |
| EBITDA | -28.4 m ≈ | -64.9 m ≈ | -87.2 m ≈ | SEC (XBRL)· 10 Mar 2026derived |
| Pre-tax income | -28.6 m | -65.4 m | — | SEC (XBRL)· 24 Mar 2025verified |
| Income tax | 72.0 k | 0 | 0 | SEC (XBRL)· 10 Mar 2026verified |
| Net income | -28.7 m | -65.4 m | -83.9 m | SEC (XBRL)· 10 Mar 2026verified |
| Diluted EPS | -35.78 | -5.81 | -3.43 | SEC (XBRL)· 10 Mar 2026verified |
| Weighted average diluted shares | 802.7 k | 11.3 m | 24.4 m | SEC (XBRL)· 10 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|
| Cash | 53.5 m | 40.2 m | 26.7 m | SEC (XBRL)· 10 Mar 2026verified |
| Receivables | 1.0 m | 0 | — | SEC (XBRL)· 24 Mar 2025verified |
| Current assets | 79.8 m | 188.6 m | 112.7 m | SEC (XBRL)· 10 Mar 2026verified |
| Property, plant & equipment, net | 8.1 m | 6.4 m | 6.6 m | SEC (XBRL)· 10 Mar 2026verified |
| Total assets | 105.1 m | 209.6 m | 130.9 m | SEC (XBRL)· 10 Mar 2026verified |
| Accounts payable | 614.0 k | 1.1 m | 355.0 k | SEC (XBRL)· 10 Mar 2026verified |
| Current liabilities | 12.2 m | 12.3 m | 13.1 m | SEC (XBRL)· 10 Mar 2026verified |
| Total liabilities | 50.7 m | 22.9 m | 21.0 m | SEC (XBRL)· 10 Mar 2026verified |
| Equity | -162.0 m † | 186.6 m † | 110.0 m † | SEC (XBRL)· 10 Mar 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|
| Operating cash flow | -47.4 m | -55.0 m | -76.8 m | SEC (XBRL)· 10 Mar 2026verified |
| Capex | 3.3 m | 642.0 k | 2.6 m | SEC (XBRL)· 10 Mar 2026verified |
| Free cash flow | -50.7 m ≈ | -55.7 m ≈ | -79.3 m ≈ | SEC (XBRL)· 10 Mar 2026derived |
| Investing cash flow | -26.0 m | -120.5 m | 63.4 m | SEC (XBRL)· 10 Mar 2026verified |
| Financing cash flow | 24.4 m | 162.2 m | 9.0 k | SEC (XBRL)· 10 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 2 of at least 6
- score weight coverage: 12.5% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
05 Nov 2026Source: olivLaw, closing series
Market cap: 201.9 m USD
Key indicators
Coverage and freshness
Score by group
13% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · input data missing
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 2 of at least 6; score weight coverage: 12.5% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | unavailable | unavailable | — |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | unavailable | unavailable | — |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | unavailable | unavailable | — |
| Current ratio · Balance sheet | 24.2x | 100 (on a fixed band) | 33% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | -38.1% | 0 (on a fixed band) | 67% |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet· partial100/100 · 1/3 factors with a value
- Growth· partialunavailable · 0/2 factors with a value
- Quality· partialunavailable · 0/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partial0/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
Artiva Biotherapeutics, Inc. (ARTV). Latest full fiscal year: 2025; data up to 2026-06-30.
Figures computed from the financial statements: revenue 0 USD in 2025; YoY growth -100.0%; ROE -36.6%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 2 of at least 6; score weight coverage: 12.5% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Current ratio: 24.2x
What contradicts it
- FCF yield: -38.1%
Not assessed (insufficient data or a ratio without meaning): ROIC, Net margin, FCF conversion, Revenue CAGR 3Y, EPS CAGR 3Y, Net debt / EBITDA, Interest coverage, P/E (TTM), EV/EBITDA, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Biological Products, (No Diagnostic Substances) (SIC 2836) · same industry (4-digit SIC) · compared with 39 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| AMGNAmgen Inc. | 258.8 bn | 27.7 | 78.4% | 24.1% | +10.0% | +39% / +77% |
| GILDGilead Sciences, Inc. | 216.4 bn | — | -22.3% | -12.5% | +2.4% | +39% / +128% |
| MRNAModerna, Inc. | 103.2 bn | — | -39.0% | -141.4% | −39.9% | +895% / +233% |
| RVMDRevolution Medicines, Inc. | 43.2 bn | — | -93.6% | -946.8% | unavailable | +157% / +756% |
| BIIBBiogen Inc. | 37.6 bn | 108.8 | 1.9% | 3.4% | +2.2% | +40% / +9% |
| MESOMesoblast Limited | 18.3 bn | — | -19.0% | -593.9% | +191.4% | −18% / +418% |
| EXELExelixis, Inc. | 17.8 bn | 21.7 | 44.3% | 35.5% | +7.0% | +65% / +234% |
| NBIXNeurocrine Biosciences, Inc. | 16.2 bn | 23.7 | 20.4% | 19.0% | +21.4% | +5% / +37% |
| KYMRKymera Therapeutics, Inc. | 10.9 bn | — | -27.3% | -341.8% | −16.7% | +89% / +517% |
| ADPTAdaptive Biotechnologies Corporation | 4.3 bn | — | -37.1% | -23.7% | +54.8% | +36% / +513% |
| RLAYRelay Therapeutics, Inc. | 3.8 bn | — | -41.2% | -2,837.0% | +53.4% | +115% / +115% |
| ADMAAdma Biologics, Inc. | 2.9 bn | 17.1 | 41.9% | 35.1% | +19.6% | −31% / +257% |
| BEAMBeam Therapeutics Inc. | 2.7 bn | — | -11.3% | -73.9% | +120.0% | +2% / −8% |
| VCELVericel Corporation | 2.7 bn | 122.6 | 7.2% | 7.9% | +16.5% | +29% / +46% |
| BCRXBiocryst Pharmaceuticals, Inc. | 2.0 bn | — | — | -37.4% | +94.1% | +6% / +30% |
| REPLReplimune Group, Inc. | 1.9 bn | — | -115.8% | — | unavailable | +100% / +79% |
| VIRVir Biotechnology, Inc. | 1.9 bn | — | -21.8% | -61.0% | −7.6% | +72% / +16% |
| MAZEMaze Therapeutics, Inc. | 1.8 bn | — | -37.3% | -5,343.6% | unavailable | −14% / unavailable |
| INBXInhibrx Biosciences, Inc. | 1.2 bn | — | -1,773.6% | — | +550.0% | −5% / unavailable |
| GLUEMonte Rosa Therapeutics, Inc. | 874.5 m | — | -42.7% | -560.9% | +63.5% | −37% / +231% |
| XFORX4 Pharmaceuticals, Inc | 313.5 m | — | -80.3% | -813.3% | +150.0% | −16% / −87% |
| SABSSab Biotherapeutics, Inc. | 267.5 m | — | -11.3% | — | −100.0% | −26% / −70% |
| LXEOLexeo Therapeutics, Inc. | 238.3 m | — | -46.8% | — | unavailable | −71% / −77% |
| PALIPalisade Bio, Inc. | 202.2 m | — | -51.4% | -6,388.2% | unavailable | −45% / −88% |
| ARTVArtiva Biotherapeutics, Inc. | 201.9 m | — | -36.6% | — | −100.0% | +20% / unavailable |
1- and 3-year price returns: for ARTV from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Scenarios are not available. input data missing
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 06 Aug 2026; since then the company filed 8-K (27 Oct 2026 · results).
In brief
Artiva Biotherapeutics develops off-the-shelf allogeneic NK cell therapies for B-cell driven autoimmune diseases, mainly refractory rheumatoid arthritis. In 2026 the company announced a Phase 3 design aligned with the FDA and a financing of about 300 million USD, which makes it relevant to the clinical stage of AlloNK 23.
SWOT
Strengths
- Initial clinical data show deep B-cell depletion and no CRS or ICANS reported in the outpatient-administered cohort 23. The company has obtained accelerated regulatory designations and a study design aligned with the FDA 2.
- A scalable, cryopreserved production process that may lower per-patient costs compared with autologous therapies 1.
- A consolidated cash position after an underwritten offering that supports the Phase 3 plan 3.
Weaknesses
- The company has no approved product and no product revenue, and losses continue 1.
- The clinical data are preliminary, come from small studies and combine cohorts with different designs, which limits comparisons 23.
- Dependence on one main product, AlloNK, exposes the company to clinical or manufacturing setbacks 1.
Opportunities
- If the Phase 3 study in refractory rheumatoid arthritis confirms the benefit, the company could open an important market for patients who have failed several treatments 2.
- Expansion into Sjögren disease, systemic sclerosis and myositis could broaden the indications for AlloNK 3.
- Outpatient administration in community clinics could widen access to treatment and may reduce health system costs 13.
Threats
- A failure of the Phase 3 study or regulatory delays could reduce the programme's value and force the company to scale back activities 12.
- The need for additional funding may lead to shareholder dilution or agreements with restrictive conditions 1.
- Competition from approved therapies and new treatment classes could limit market share 1.
Risks
- Dependence on a single producthigh
Most of the company's activities depend on AlloNK; safety, efficacy or manufacturing problems could affect all programmes 1.
- Funding needshigh
The company will need additional capital to complete studies and commercialization, and access to financing may be limited 13.
- Regulatory riskmedium
RMAT designation and FDA alignment do not guarantee clinical success or rapid approval, as the company itself notes 12.
- Donor-to-donor variabilitymedium
Primary cells vary between donors, which may complicate standardization and consistent production 1.
- Development in new indicationslow
The NK approach in autoimmune disease is novel with limited experience, and any adverse effects could change the development plan 1.
Investment thesis
What would need to be true (bull case)
- If Phase 3 data confirm the response rate seen in the Phase 2a study, the company could have a fast path to approval in an indication with high medical need 23.
- The safety profile reported so far, with outpatient administration and no CRS or ICANS, could become a competitive advantage over CAR-T therapies 13.
- The cash position after the 2026 offering could cover the study plan without an immediate new round of funding, if spending stays stable 3.
What would break the thesis
- The clinical data are still preliminary, with a small number of patients and short follow-up for many cases, which could change conclusions as the study expands 23.
- The company keeps losing money and has no product revenue, so the outcome depends entirely on the success of a single programme 1.
- If Phase 3 results are weaker than the company's expectations, the value of the programme could decline significantly 2.
What to watch
- Start of the Phase 3 study in refractory rheumatoid arthritissecond half 2026
- Final Phase 3 results and longer-term ACR50 ratesnext 10-K
- Cash burn compared with the estimate of funding operations into 2029Q4 2026
- Results for Sjögren disease and systemic sclerosis from sponsored studies2027
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 06 Aug 2026; since then the company filed 8-K (27 Oct 2026 · results).
The business
In 2026 the strategy centred on refractory rheumatoid arthritis, where AlloNK is given together with rituximab. The RMAT designation from June 2026 and the FDA alignment on a randomized study of about 150 patients support the registrational plan 23. If Phase 3 data confirm the benefit, the company could move toward a marketing application, but this step remains conditional on future clinical results 2.
Financially, Artiva reported cash, cash equivalents and investments of 349.4 million USD as of June 30, 2026, which it expects to fund operations into 2029 3. The net loss for the second quarter of 2026 was 25.0 million USD 3. The company is listed on Nasdaq as ARTV and is headquartered in San Diego, California 3.
Segments
AlloNK in refractory rheumatoid arthritis
This is the priority programme. The initial dataset includes 21 patients with at least 12 weeks of follow-up, and among patients with six months of follow-up the ACR50 response rate was 71% 23. The planned Phase 3 study targets about 150 patients with an inadequate response to at least two b/tsDMARD classes 2.
AlloNK in Sjögren disease and systemic sclerosis
Secondary programmes include Sjögren disease and systemic sclerosis, where the company reports clinical and functional improvements in patients followed for medium term 3. The data are more limited and come from small cohorts, so their interpretation stays cautious 3.
Market context
The company argues that a manufacturing cost of 3,000 to 12,000 USD per patient could allow more flexible pricing and payor coverage than autologous CAR-T, whose cost of goods exceeds 100,000 USD per treatment course 1. Its current facility could in principle treat about 1,000 patients per year 1. These are the company's own estimates and not commercial confirmations.
Trends
- Substitution of CAR-T by allogeneic approachestailwind
The limits of autologous CAR-T, such as cost, hospitalization and scalability, open room for off-the-shelf therapies, if outpatient safety evidence is confirmed 13.
- Regulatory interest in cell therapiestailwind
Fast Track and RMAT designations for AlloNK show that regulators are willing to accelerate development in serious indications, which could shorten the review timeline 2.
- Intense competition in autoimmune diseaseheadwind
Anti-CD20 antibodies, JAK inhibitors and T-cell engager technologies compete for the same patients, which may limit the market share of a new therapy 1.
- Financing and dilutionmixed
Reliance on equity financing for clinical studies can dilute shareholders, but the current cash position temporarily reduces this pressure 13.
Competitive position
Competition includes autologous CAR-T therapies already approved for haematological malignancies, as well as efforts to extend them to autoimmune diseases. T-cell engagers are another competing category, with advantages in patient access but higher safety risks 1.
Artiva argues that its edge lies in outpatient administration in community rheumatology clinics and in a much lower production cost 13. The sources, however, do not identify other direct competitors with comparable clinical data in the same indication 1.
- Autologous CAR-T therapies (approved class)
Autologous cell therapies that have shown deep B-cell depletion but with higher cost and hospitalization requirements 1.
- T-cell engagers
Alternative approach to B-cell depletion with advantages in accessibility and scalability but with documented safety risks 1.
- Anti-CD20 antibodies
The backbone therapy with which AlloNK is combined and a comparison standard in the Phase 3 study 23.
- JAK inhibitors and other b/tsDMARDs
Treatment classes approved for rheumatoid arthritis that define the refractory patient population the company targets 1.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
- STAT+: After two deaths in autoimmune cell therapy trial, Artiva is shutting downSTAT News · 27 Oct 2026 · EN
SEC filings
- Current report27 Oct 2026Results of operations · Exit or disposal costs · Financial statements and exhibits
- Current report11 Sept 2026Departure or appointment of officers · Shareholder vote · Financial statements and exhibits
- Quarterly report06 Aug 2026
- Current report06 Aug 2026Results of operations · Financial statements and exhibits
- Proxy statement03 Aug 2026
- Current report22 Jul 2026Other events
- Current report19 May 2026Departure or appointment of officers
- Current report08 May 2026Other events · Financial statements and exhibits
- Quarterly report08 May 2026
- Current report08 May 2026Results of operations · Regulation FD disclosure · Other events · Financial statements and exhibits
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / Artiva Biotherapeutics, Inc. · 10 Mar 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / Artiva Biotherapeutics, Inc. · 06 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / Artiva Biotherapeutics, Inc. · 06 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.